Navigation Links
Accuray Prices Offering Of $100 Million Of 3.50% Convertible Senior Notes
Date:2/8/2013

SUNNYVALE, Calif., Feb. 8, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) ("Accuray") today announced the pricing of its offering of $100 million aggregate principal amount of 3.50% convertible senior notes due 2018 (the "notes"). The notes are being offered and sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The sale is expected to close on February 13, 2013. Accuray has also granted to the initial purchasers of the notes the right to purchase up to an additional $15 million aggregate principal amount of notes.

Interest will be payable on the notes semi-annually in arrears at a rate of 3.50% per annum. The notes will be convertible into common stock of Accuray.  The initial conversion rate for the notes will be 187.6877 shares of common stock per $1,000 principal amount of the notes, which is equivalent to an initial conversion price of approximately $5.33 per share, representing an approximately 20.0% conversion premium based on the closing sale price of Accuray's common stock of $4.44 per share on February 7, 2013. The notes will mature on February 1, 2018.

Accuray may not redeem the notes prior the maturity date. 

Accuray's purpose for the offering is to strengthen its balance sheet in order to help improve its competitive position.  It intends to use the net proceeds from the offering for general corporate purposes, including investing strategically in expanding its business and new product initiatives.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.

The notes and any shares of common stock issuable upon conversion of the notes have not been and are not expected to be registered under the Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to any U.S. persons absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state laws.

Safe Harbor Statement
The matters discussed in this release include forward-looking statements. These statements are based on current expectations or beliefs and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including without limitation, the anticipated use of the proceeds of the offering. Accuray is providing this information as of the date of this news release and assumes no obligation to update any forward-looking statement to reflect events or circumstances occurring after the date of this press release.

 


'/>"/>
SOURCE Accuray Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
2. Accuray Announces Results for Third Quarter Fiscal 2012
3. Accuray Appoints Richard Pettingill, LFACHE to Board of Directors
4. Accuray and the German Cancer Research Center Sign Master Research and Collaboration Agreement
5. Accuray Incorporated to Speak at Jefferies Global Healthcare Conference
6. Accuray Incorporated to Speak at Wells Fargo Healthcare Conference
7. Accuray Rolls Out Comprehensive Customer Service Program in Japan
8. One Year After TomoTherapy Acquisition, Accuray on Track to Meet or Exceed Integration Success Metrics And Expecting Near-term Return to Profitability
9. Accuray and Erasmus Medical Center Sign Master Research and Collaboration Agreement
10. Accuray to Acquire Morphormics, Inc.
11. Accuray Incorporateds CEO to Speak at Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ISELIN, New Jersey , April 29, 2016 ... Omnichannel Software Suite for Life Sciences, Product Development ... and Global Life Science Customer Base . ... healthcare solutions provider, today announced the acquisition of ... is a global leader in adaptive sales enablement ...
(Date:4/29/2016)... April 29, 2016 Glycotope GmbH, ... today announces the appointment of Dr. Alfredo Zurlo ... is an oncologist with many years clinical experience and ... industries. His last role was at Mologen AG where ... Executive Board. Previously Dr. Zurlo held various positions at ...
(Date:4/28/2016)... April 28, 2016   Click here for ... Inc. (NYSE: DPLO), the nation,s largest independent specialty ... definitive agreement to acquire Valley Campus Pharmacy, Inc., ... a leading specialty pharmacy that provides individualized patient ... . In 2015, TNH generated approximately $400 ...
Breaking Medicine Technology:
(Date:5/1/2016)... ... , ... ProBrand Reveal Volume 2 is a set of versatile and smooth logo reveals built ... users can easily create a unique logo reveal in just a matter of minutes. Custom ... these title presets to add a uniquely animated logo to any photos or videos. , ...
(Date:4/30/2016)... ... May 01, 2016 , ... Serenity Recovery, a substance abuse ... produced a new video that focuses on one of the more popular of their ... clips from interviews with a participating patients and the Yoga class instructor, this video ...
(Date:4/30/2016)... , ... April 30, 2016 , ... ... announced RANKED Health , a program to critically evaluate and rank health-focused ... of the program is to provide independent, unbiased and accurate information to help ...
(Date:4/30/2016)... ... April 30, 2016 , ... ... 4th, 2016 questioned the use of the HyProCure sinus tarsi implant. ( ... procedure.” EOTTS-HyProCure is a minimally invasive procedure performed, when indicated, to correct ...
(Date:4/29/2016)... ... 30, 2016 , ... World Patent Marketing , a ... an automotive invention that improves the storage features of a pick up truck. ... Scott Cooper, CEO and Creative Director of World Patent Marketing. "Over the next ...
Breaking Medicine News(10 mins):